Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
5
PBLA Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-13.55%
Day range:
$0.0001 - $0.0111
52-week range:
$0.0000 - $0.4729
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.48x
P/B ratio:
--
Volume:
129.5K
Avg. volume:
5.7K
1-year change:
-99.7%
Market cap:
$5.3K
Revenue:
--
EPS (TTM):
-$18.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBLA
Panbela Therapeutics, Inc.
|
-- | -$1.70 | -- | -97.75% | -- |
|
AMPE
Ampio Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
FNAM
Evolutionary Genomics, Inc.
|
-- | -- | -- | -- | -- |
|
FPMI
FluoroPharma Medical, Inc.
|
-- | -- | -- | -- | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
-- | -- | -- | -- | -- |
|
MTST
MetaStat, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBLA
Panbela Therapeutics, Inc.
|
$0.0011 | -- | $5.3K | -- | $0.00 | 0% | 0.48x |
|
AMPE
Ampio Pharmaceuticals, Inc.
|
$0.0055 | -- | $6.2K | -- | $0.00 | 0% | -- |
|
FNAM
Evolutionary Genomics, Inc.
|
$0.0002 | -- | $1.3K | -- | $0.00 | 0% | 0.01x |
|
FPMI
FluoroPharma Medical, Inc.
|
$0.0002 | -- | $6.9K | -- | $0.00 | 0% | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
$0.0000 | -- | $1.2K | -- | $0.00 | 0% | -- |
|
MTST
MetaStat, Inc.
|
$0.0007 | -- | $4.1K | -- | $0.00 | 0% | 0.16x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBLA
Panbela Therapeutics, Inc.
|
-- | -2.093 | -- | -- |
|
AMPE
Ampio Pharmaceuticals, Inc.
|
-- | 12.603 | -- | -- |
|
FNAM
Evolutionary Genomics, Inc.
|
-- | 1.160 | -- | -- |
|
FPMI
FluoroPharma Medical, Inc.
|
-- | -0.823 | -- | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
-- | -0.098 | -- | -- |
|
MTST
MetaStat, Inc.
|
-- | 2,649.282 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBLA
Panbela Therapeutics, Inc.
|
-- | -$7.2M | -- | -- | -- | -$2.1M |
|
AMPE
Ampio Pharmaceuticals, Inc.
|
-- | -$2.2M | -- | -- | -- | -$2.3M |
|
FNAM
Evolutionary Genomics, Inc.
|
-- | -- | -- | -- | -- | -- |
|
FPMI
FluoroPharma Medical, Inc.
|
-- | -- | -- | -- | -- | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
-- | -$193.4K | -- | -- | -- | -$20.4K |
|
MTST
MetaStat, Inc.
|
-- | -- | -- | -- | -- | -- |
Panbela Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PBLA or AMPE?
Ampio Pharmaceuticals, Inc. has a net margin of -- compared to Panbela Therapeutics, Inc.'s net margin of --. Panbela Therapeutics, Inc.'s return on equity of -- beat Ampio Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBLAPanbela Therapeutics, Inc.-- -$1.48 -- AMPEAmpio Pharmaceuticals, Inc.-- -$2.48 -- -
What do Analysts Say About PBLA or AMPE?
Panbela Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 45454445.46%. On the other hand Ampio Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 10908985.46%. Given that Panbela Therapeutics, Inc. has higher upside potential than Ampio Pharmaceuticals, Inc., analysts believe Panbela Therapeutics, Inc. is more attractive than Ampio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBLAPanbela Therapeutics, Inc.0 0 0 AMPEAmpio Pharmaceuticals, Inc.0 0 0 -
Is PBLA or AMPE More Risky?
Panbela Therapeutics, Inc. has a beta of 1.122, which suggesting that the stock is 12.214% more volatile than S&P 500. In comparison Ampio Pharmaceuticals, Inc. has a beta of 4.687, suggesting its more volatile than the S&P 500 by 368.733%.
-
Which is a Better Dividend Stock PBLA or AMPE?
Panbela Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ampio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Panbela Therapeutics, Inc. pays -- of its earnings as a dividend. Ampio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBLA or AMPE?
Panbela Therapeutics, Inc. quarterly revenues are --, which are smaller than Ampio Pharmaceuticals, Inc. quarterly revenues of --. Panbela Therapeutics, Inc.'s net income of -$7.2M is lower than Ampio Pharmaceuticals, Inc.'s net income of -$2.1M. Notably, Panbela Therapeutics, Inc.'s price-to-earnings ratio is -- while Ampio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Panbela Therapeutics, Inc. is 0.48x versus -- for Ampio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBLAPanbela Therapeutics, Inc.0.48x -- -- -$7.2M AMPEAmpio Pharmaceuticals, Inc.-- -- -- -$2.1M
-
Which has Higher Returns PBLA or FNAM?
Evolutionary Genomics, Inc. has a net margin of -- compared to Panbela Therapeutics, Inc.'s net margin of --. Panbela Therapeutics, Inc.'s return on equity of -- beat Evolutionary Genomics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBLAPanbela Therapeutics, Inc.-- -$1.48 -- FNAMEvolutionary Genomics, Inc.-- -- -- -
What do Analysts Say About PBLA or FNAM?
Panbela Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 45454445.46%. On the other hand Evolutionary Genomics, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Panbela Therapeutics, Inc. has higher upside potential than Evolutionary Genomics, Inc., analysts believe Panbela Therapeutics, Inc. is more attractive than Evolutionary Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBLAPanbela Therapeutics, Inc.0 0 0 FNAMEvolutionary Genomics, Inc.0 0 0 -
Is PBLA or FNAM More Risky?
Panbela Therapeutics, Inc. has a beta of 1.122, which suggesting that the stock is 12.214% more volatile than S&P 500. In comparison Evolutionary Genomics, Inc. has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.303%.
-
Which is a Better Dividend Stock PBLA or FNAM?
Panbela Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolutionary Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Panbela Therapeutics, Inc. pays -- of its earnings as a dividend. Evolutionary Genomics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBLA or FNAM?
Panbela Therapeutics, Inc. quarterly revenues are --, which are smaller than Evolutionary Genomics, Inc. quarterly revenues of --. Panbela Therapeutics, Inc.'s net income of -$7.2M is higher than Evolutionary Genomics, Inc.'s net income of --. Notably, Panbela Therapeutics, Inc.'s price-to-earnings ratio is -- while Evolutionary Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Panbela Therapeutics, Inc. is 0.48x versus 0.01x for Evolutionary Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBLAPanbela Therapeutics, Inc.0.48x -- -- -$7.2M FNAMEvolutionary Genomics, Inc.0.01x -- -- --
-
Which has Higher Returns PBLA or FPMI?
FluoroPharma Medical, Inc. has a net margin of -- compared to Panbela Therapeutics, Inc.'s net margin of --. Panbela Therapeutics, Inc.'s return on equity of -- beat FluoroPharma Medical, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBLAPanbela Therapeutics, Inc.-- -$1.48 -- FPMIFluoroPharma Medical, Inc.-- -- -- -
What do Analysts Say About PBLA or FPMI?
Panbela Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 45454445.46%. On the other hand FluoroPharma Medical, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Panbela Therapeutics, Inc. has higher upside potential than FluoroPharma Medical, Inc., analysts believe Panbela Therapeutics, Inc. is more attractive than FluoroPharma Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBLAPanbela Therapeutics, Inc.0 0 0 FPMIFluoroPharma Medical, Inc.0 0 0 -
Is PBLA or FPMI More Risky?
Panbela Therapeutics, Inc. has a beta of 1.122, which suggesting that the stock is 12.214% more volatile than S&P 500. In comparison FluoroPharma Medical, Inc. has a beta of -98.500, suggesting its less volatile than the S&P 500 by 9950.016%.
-
Which is a Better Dividend Stock PBLA or FPMI?
Panbela Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FluoroPharma Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Panbela Therapeutics, Inc. pays -- of its earnings as a dividend. FluoroPharma Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBLA or FPMI?
Panbela Therapeutics, Inc. quarterly revenues are --, which are smaller than FluoroPharma Medical, Inc. quarterly revenues of --. Panbela Therapeutics, Inc.'s net income of -$7.2M is higher than FluoroPharma Medical, Inc.'s net income of --. Notably, Panbela Therapeutics, Inc.'s price-to-earnings ratio is -- while FluoroPharma Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Panbela Therapeutics, Inc. is 0.48x versus -- for FluoroPharma Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBLAPanbela Therapeutics, Inc.0.48x -- -- -$7.2M FPMIFluoroPharma Medical, Inc.-- -- -- --
-
Which has Higher Returns PBLA or GSTC?
GlobeStar Therapeutics Corp. has a net margin of -- compared to Panbela Therapeutics, Inc.'s net margin of --. Panbela Therapeutics, Inc.'s return on equity of -- beat GlobeStar Therapeutics Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBLAPanbela Therapeutics, Inc.-- -$1.48 -- GSTCGlobeStar Therapeutics Corp.-- -$0.00 -- -
What do Analysts Say About PBLA or GSTC?
Panbela Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 45454445.46%. On the other hand GlobeStar Therapeutics Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Panbela Therapeutics, Inc. has higher upside potential than GlobeStar Therapeutics Corp., analysts believe Panbela Therapeutics, Inc. is more attractive than GlobeStar Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings PBLAPanbela Therapeutics, Inc.0 0 0 GSTCGlobeStar Therapeutics Corp.0 0 0 -
Is PBLA or GSTC More Risky?
Panbela Therapeutics, Inc. has a beta of 1.122, which suggesting that the stock is 12.214% more volatile than S&P 500. In comparison GlobeStar Therapeutics Corp. has a beta of 1.276, suggesting its more volatile than the S&P 500 by 27.621%.
-
Which is a Better Dividend Stock PBLA or GSTC?
Panbela Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlobeStar Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Panbela Therapeutics, Inc. pays -- of its earnings as a dividend. GlobeStar Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBLA or GSTC?
Panbela Therapeutics, Inc. quarterly revenues are --, which are smaller than GlobeStar Therapeutics Corp. quarterly revenues of --. Panbela Therapeutics, Inc.'s net income of -$7.2M is lower than GlobeStar Therapeutics Corp.'s net income of -$197.7K. Notably, Panbela Therapeutics, Inc.'s price-to-earnings ratio is -- while GlobeStar Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Panbela Therapeutics, Inc. is 0.48x versus -- for GlobeStar Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBLAPanbela Therapeutics, Inc.0.48x -- -- -$7.2M GSTCGlobeStar Therapeutics Corp.-- -- -- -$197.7K
-
Which has Higher Returns PBLA or MTST?
MetaStat, Inc. has a net margin of -- compared to Panbela Therapeutics, Inc.'s net margin of --. Panbela Therapeutics, Inc.'s return on equity of -- beat MetaStat, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBLAPanbela Therapeutics, Inc.-- -$1.48 -- MTSTMetaStat, Inc.-- -- -- -
What do Analysts Say About PBLA or MTST?
Panbela Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 45454445.46%. On the other hand MetaStat, Inc. has an analysts' consensus of -- which suggests that it could grow by 1571328.57%. Given that Panbela Therapeutics, Inc. has higher upside potential than MetaStat, Inc., analysts believe Panbela Therapeutics, Inc. is more attractive than MetaStat, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBLAPanbela Therapeutics, Inc.0 0 0 MTSTMetaStat, Inc.0 0 0 -
Is PBLA or MTST More Risky?
Panbela Therapeutics, Inc. has a beta of 1.122, which suggesting that the stock is 12.214% more volatile than S&P 500. In comparison MetaStat, Inc. has a beta of 299.297, suggesting its more volatile than the S&P 500 by 29829.718%.
-
Which is a Better Dividend Stock PBLA or MTST?
Panbela Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaStat, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Panbela Therapeutics, Inc. pays -- of its earnings as a dividend. MetaStat, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBLA or MTST?
Panbela Therapeutics, Inc. quarterly revenues are --, which are smaller than MetaStat, Inc. quarterly revenues of --. Panbela Therapeutics, Inc.'s net income of -$7.2M is higher than MetaStat, Inc.'s net income of --. Notably, Panbela Therapeutics, Inc.'s price-to-earnings ratio is -- while MetaStat, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Panbela Therapeutics, Inc. is 0.48x versus 0.16x for MetaStat, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBLAPanbela Therapeutics, Inc.0.48x -- -- -$7.2M MTSTMetaStat, Inc.0.16x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
